SODIUM PHOSPHATE P 32 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sodium Phosphate P 32, and what generic alternatives are available?
Sodium Phosphate P 32 is a drug marketed by Mallinckrodt and is included in one NDA.
The generic ingredient in SODIUM PHOSPHATE P 32 is sodium phosphate p-32. There are one thousand four hundred and seventy-two drug master file entries for this compound. Additional details are available on the sodium phosphate p-32 profile page.
Summary for SODIUM PHOSPHATE P 32
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 8 |
| Clinical Trials: | 173 |
| Patent Applications: | 2 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | SODIUM PHOSPHATE P 32 at DailyMed |
Recent Clinical Trials for SODIUM PHOSPHATE P 32
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Collegium Medicum w Bydgoszczy | Phase 3 |
| Aarhus University Hospital, Department of Nephrology | Phase 4 |
| Khyber Medical College, Peshawar | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for SODIUM PHOSPHATE P 32
US Patents and Regulatory Information for SODIUM PHOSPHATE P 32
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt | SODIUM PHOSPHATE P 32 | sodium phosphate p-32 | SOLUTION;INJECTION, ORAL | 011777-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Mallinckrodt | SODIUM PHOSPHATE P 32 | sodium phosphate p-32 | SOLUTION;INJECTION, ORAL | 011777-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
